Clinton Snow
Director/Board Member chez ICETANA LIMITED
Profil
Clinton Snow is currently a Non-Executive Director at Dimerix Ltd., PolyActiva Pty Ltd., and iCetana Ltd.
He completed his undergraduate degree at the University of Melbourne.
Postes actifs de Clinton Snow
| Sociétés | Poste | Début |
|---|---|---|
| ICETANA LIMITED | Director/Board Member | 08/02/2022 |
| DIMERIX LIMITED | Director/Board Member | 01/05/2023 |
PolyActiva Pty Ltd.
 PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Director/Board Member | - |
Formation de Clinton Snow
| University of Melbourne | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DIMERIX LIMITED | Health Technology |
| ICETANA LIMITED | Technology Services |
| Entreprise privées | 1 |
|---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
